Trial Profile

A Phase 2b Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy Versus Bulevirtide in Participants With Chronic HDV Infection (ECLIPSE 3)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 29 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Dec 2025 According to a Vir Biotechnology media release, clinical development costs for the ongoing trials in the ECLIPSE registrational program (ECLIPSE 1, 2 and 3) will be shared, where Norgine will contribute around 25% of go-forward external costs.
16 Dec 2025 According to Vir Biotechnology media release, status changed from recruiting to active, no longer recruiting.
05 Nov 2025 According to Vir Biotechnology media release, topline data expected in the first quarter of 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com